

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	
	)	Confirmation No. 2944
Roger John Gillespie et al.	)	Group Art No. 1614
	)	
Serial No: 10/588,757	)	Examiner: Christopher R. Stone
	)	
Filed: June 25, 2007	)	Docket No. 010180.00052

For: *Pyrimidine Compounds As Purine Receptor Antagonist*

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This paper is responsive to the Restriction Requirement dated April 10, 2008, in connection with the above-identified application.

In response to the Restriction Requirement, Applicants elect, without traverse, the invention of Group II, claims 19-23, drawn to compounds. Applicants retain the right of rejoinder.

In response to the election of species requirement, Applicants elect the species of Example 1. Claims 19 and 21-23 read on the elected species.

Applicants reserve the right to file a divisional application directed to the non-elected inventions prior to the termination of proceedings in this application.

It is believed that no fee is due for filing this response. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: May 9, 2008

By: /Susan A. Wolffe/  
Susan A. Wolffe  
Registration No. 33,568

1100 13<sup>th</sup> Street  
Suite 1200  
Washington, D.C. 20005  
(202) 824-3000